Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs & symptoms of blepharitis and tear cytokine and eyelid bacterial load levels

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Azithromycin; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Diagnosis of moderate to severe chronic blepharitis

• If female of childbearing potential, are non-pregnant and non-lactating

Exclusion Criteria:

• Had ocular surface surgery (LASIK, refractive, etc.) within the past year

• Unwilling to discontinue use of contact lenses during the study

• Have glaucoma

• Unable or unwilling to withhold the use of lid scrubs during the study

• Have a serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance

• Currently using any preserved topical ocular medications (with the exception of unpreserved tear substitutes) at the time of entry into the study or during study participation